Smartphone-Based Psychotherapeutic Micro-Interventions to Improve Mood in a Real-World Setting.
Smartphone-Based Psychotherapeutic Micro-Interventions to Improve Mood in a Real-World Setting.
复制标题
DOI：
10.3389/fpsyg.2016.01112
复制
发表时间：
2016
影响因子：
3.8
通讯作者：
Tegethoff M
中科院分区：
文献类型：
--
作者：
Meinlschmidt G;Lee JH;Stalujanis E;Belardi A;Oh M;Jung EK;Kim HC;Alfano J;Yoo SS;Tegethoff M
背景资料：使用移动的通信技术作为治疗精神障碍或更普遍地改善生活质量的新的个性化方法是非常有前途的。知识的干预组件，目标是关键的心理病理过程的转诊断心理治疗方法是迫切需要的。我们探索了使用基于智能手机的微干预基于心理治疗技术，由短视频剪辑引导，以引起情绪变化。方法：作为一项更大规模的神经反馈研究的一部分，所有受试者在被随机分配到实验或控制神经反馈条件后，连续13天每天接受基于智能手机的微干预。他们可以自由选择提供的技术，包括内脏感觉注意力，情感意象，面部表情和重复。在真实的世界中，使用多维情绪状态问卷（量表：好-坏，GB;清醒-疲劳，AT;和平静-神经，CN）评估情绪变化。结果：27名男性参与了至少11天，因此被纳入分析。总共，他们进行了335次，一般耐受良好，微干预会议，内脏感觉注意（178次，53.13%）和重复（68次，20.30%）是最常用的技术。混合模型表明受试者表现出更好的情绪[GB：B = 0.464，95%可信区间（CI）[0.068，0.860]，t（613.3）= 2.298，p = 0.022]，并且变得更加清醒[AT：B = 0.514，95%CI [0.103，0.925]，t（612.4）= 2.456，p = 0.014]和从微干预前到后的平静[CN：B = 0.685，95%CI [0.360，1.010]，t（612.3）= 4.137，p < 0.001]。这些从微干预前到微干预后的情绪改善与GB情绪方面从第1天到最后一天的情绪变化相关（r = 0.614，95%CI [0.297，0.809]，p < 0.001），但不是AT情绪（r = 0.279，95%CI [-0.122，0.602]，p = 0.167）和CN情绪（r = 0.277，95%CI [0.124，0.601]，p = 0.170）。讨论内容：我们的研究结果为基于智能手机的微干预引起短期情绪变化的适用性提供了证据，基于心理治疗方法中使用的技术，如基于正念的心理治疗，超越冥想和其他冥想疗法。这些结果鼓励在随机对照研究和患者中探索这些技术改善情绪的能力。基于智能手机的微干预有望在现实世界中改变情绪，补充其他心理治疗干预措施，符合精准医学方法。本文提供的数据是在一项随机试验中收集的，在ClinicalTrials.gov（标识符：NCT 01921088）https://clinicaltrials.gov/ct2/show/NCT01921088注册。
Background: Using mobile communication technology as new personalized approach to treat mental disorders or to more generally improve quality of life is highly promising. Knowledge about intervention components that target key psychopathological processes in terms of transdiagnostic psychotherapy approaches is urgently needed. We explored the use of smartphone-based micro-interventions based on psychotherapeutic techniques, guided by short video-clips, to elicit mood changes. Method: As part of a larger neurofeedback study, all subjects—after being randomly assigned to an experimental or control neurofeedback condition—underwent daily smartphone-based micro-interventions for 13 consecutive days. They were free to choose out of provided techniques, including viscerosensory attention, emotional imagery, facial expression, and contemplative repetition. Changes in mood were assessed in real world using the Multidimensional Mood State Questionnaire (scales: good–bad, GB; awake–tired, AT; and calm–nervous, CN). Results: Twenty-seven men participated on at least 11 days and were thus included in the analyses. Altogether, they underwent 335, generally well-tolerated, micro-intervention sessions, with viscerosensory attention (178 sessions, 53.13%) and contemplative repetition (68 sessions, 20.30%) being the most frequently applied techniques. Mixed models indicated that subjects showed better mood [GB: b = 0.464, 95%confidence interval (CI) [0.068, 0.860], t(613.3) = 2.298, p = 0.022] and became more awake [AT: b = 0.514, 95%CI [0.103, 0.925], t(612.4) = 2.456, p = 0.014] and calmer [CN: b = 0.685, 95%CI [0.360, 1.010], t(612.3) = 4.137, p < 0.001] from pre- to post-micro-intervention. These mood improvements from pre- to post-micro-intervention were associated with changes in mood from the 1st day until the last day with regard to GB mood (r = 0.614, 95%CI [0.297, 0.809], p < 0.001), but not AT mood (r = 0.279, 95%CI [−0.122, 0.602], p = 0.167) and CN mood (r = 0.277, 95%CI [0.124, 0.601], p = 0.170). Discussion: Our findings provide evidence for the applicability of smartphone-based micro-interventions eliciting short-term mood changes, based on techniques used in psychotherapeutic approaches, such as mindfulness-based psychotherapy, transcendental meditation, and other contemplative therapies. The results encourage exploring these techniques' capability to improve mood in randomized controlled studies and patients. Smartphone-based micro-interventions are promising to modify mood in real-world settings, complementing other psychotherapeutic interventions, in line with the precision medicine approach. The here presented data were collected within a randomized trial, registered at ClinicalTrials.gov (Identifier: NCT01921088) https://clinicaltrials.gov/ct2/show/NCT01921088.